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Background: Elevated serum free fatty acids (FFAs) contribute to the pathogenesis of type-2-diabetes (T2D), and
lipotoxicity is observed in many cell types. We recently showed that simulated hyperlipidemia induces lipoapoptosis
also in GLP-1-secreting L-cells in vitro, while metformin confers lipoprotection.
The aim of this study was to determine if a high fat diet (HFD) reduces the number of enteroendocrine L-cells
and/or GLP-1 plasma levels in a rodent model, and potential effects thereupon of metformin treatment.
Methods: C57/Bl6 mice received control/HFD for 12-weeks, and oral administration of metformin/saline for the last
14 days. Blood glucose, glycosylated hemoglobin and plasma insulin and GLP-1 were determined before and after
treatment with metformin using ELISAs. GLP-1-immunopositive cells in intestinal tissue sections were quantified
using immunohistochemistry.
Results: A HFD increased blood glucose, glycosylated hemoglobin, and fasting plasma insulin (33%, 15% and 70%
increase, respectively), in conjunction with reduced oral glucose tolerance, indicating the manifestation of insulin
resistance. Metformin counteracted these adverse effects, while also reducing prandial plasma FFAs. The number of
GLP-1-positive cells was indicated to be reduced (55% reduction of the number of GLP-1-positive cells, p = 0.134),
while there was a trend toward increased prandial plasma GLP-1 despite reduced food intake following a HFD.
Conclusion: HFD-fed mice rapidly develop insulin resistance. Metformin exerts beneficial glucose lowering effects,
and is indicated to improve the incretin response. Albeit no significant effect, a HFD tends to reduce the number
of GLP-1-positive cells. However, considering concurrent normal or increased plasma GLP-1, any reduction in the
number of GLP-1-positive cells, probably does not contribute to development of the glucose intolerance, but may
contribute to progression of the diabetic state through eventual loss of a functional incretin response.
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Glucagon-like peptide-1 (GLP-1) is an incretin hormone
with insulinotropic effects, where its release in response to
food intake stimulates insulin secretion in a glucose-
dependent manner [1]. This incretin response has been
suggested to be impaired in type 2 diabetes (T2D), charac-
terized by hyperglycemia resulting from impaired insulin* Correspondence: camilla.kappe@mcb.uu.se;
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a result of reduced postprandial GLP-1 concentrations [2].
Administration of GLP-1 to patients restores glucose-
induced insulin secretion as well as the β-cells’ sensitivity
to glucose and normalizes fasting and postprandial gly-
cemia in T2D patients [3], but its application as an antidi-
abetic drug is made difficult by rapid degradation. Native
GLP-1 has a half-life of less than 2 minutes, due to deg-
radation by dipeptidyl peptidase-4 (DPP-4) ubiquitously
present in plasma. Stable analogs of GLP-1 and DPP-4-
blocking agents that inhibit the degradation of active
GLP-1 (7–36) amide to its metabolite GLP-1 (9–36) are
available as treatments for T2D. Enhancing endogenousLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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secretion, and promotion of growth and viability, of L-cells
may be a novel and more physiological option in incretin-
based diabetes therapy. Enteroendocrine L-cells dispersed
along the distal intestinal tract are the main source of
endogenous GLP-1 secretion. Situated on the villi lining
the intestine, the L-cells have apical microvilli facing the
gut lumen and secretory vesicles located adjacent to the
basolateral membrane. This morphology also enables
the L-cells to be regulated by neuronal factors and hor-
mones, as well as by direct nutrient stimulation [4,5].
Free fatty acids (FFAs) are known to be potent stimula-
tors of GLP-1 secretion, as we and others have demon-
strated in vitro [6]. FFAs also acutely stimulate GLP-1
secretion in vivo [7,8], where unsaturated fatty acids
have proven more potent stimulators of incretin secre-
tion than saturated ones [9].
Chronically elevated levels of circulating FFAs and
hyperlipidemia, typically seen in T2D, are correlated to
lipotoxicity and cellular dysfunction in many cell types.
It has been reported that such lipotoxicity is induced
when the capacity of the tissue for triglyceride storage is
exceeded and the fatty acids are funneled towards other
metabolic fates, such as β-oxidation and increased pro-
duction of reactive oxygen species (ROS) [10]. In this
context, it has also been shown that unsaturated fatty
acids protect from saturated fatty acid-induced lipotoxi-
city through preventing increased β-oxidation and ROS
production by promoting triglyceride storage of lipids
[10]. This could be a result of increased solubility/stabil-
ity of lipid droplets containing a higher percentage of
unsaturated acyl chains [11].
Considering the link between obesity and T2D, reduced
GLP-1 secretion in T2D, progressively diminished GLP-1
secretory response with increasing BMI [12], as well as the
fact that high levels of FFAs induce apoptosis in a number
of different cell types, we investigated if hyperlipidemia
could result in increased apoptosis, and thus reduced GLP-
1-positive cell number and GLP-1 secretory capacity - using
an in vitro model. Our results [6,13] demonstrate that
simulated hyperlipidemia does indeed induce apoptosis
of GLP-1-secreting cells, through increased production
of ROS. We also found that the most widely prescribed
anti-diabetic drug, metformin, confers lipoprotection of
GLP-1-secreting cells in vitro [6,13]. These results may
provide an explanation to the increased levels of circu-
lating GLP-1 in obese patients (with or without T2D)
receiving metformin [14].
Leveraging the above findings, the aim of the present
study was to determine whether a high fat diet (HFD) can
reduce the number of enteroendocrine L-cells in vivo in a
rodent model. In addition, we aimed to determine the
effects of HFD treatment on GLP-1 plasma levels and
possible effects of metformin on these parameters.Materials and methods
Animals and diet
The use of laboratory animals was performed according
to the guidelines of Karolinska Institutet, Sweden, in ac-
cordance with national law and approved by the local
animal ethics committee (Stockholm South Animal Ethics
Committee, permit # S30-12).
C57/Bl6 mice (Nova/Scanbur, Sollentuna, Sweden) ar-
rived 9 weeks old and were housed in our animal depart-
ment for 1 week prior to initiation of the study. Animals
were housed in groups of four in a total of eight cages
under standard laboratory conditions of light, temperature
and humidity, and received food and water ad libitum.
Metformin was purchased from Sigma-Aldrich, St. Louis,
MO. At the initiation of the study, the animals were di-
vided into two groups. One group received normal chow
(Nova/Scanbur) and the other group received the fat-
enriched D12492 diet consisting of 60% kcal% fat
(Research Diets, New Brunswick, NJ). Since we aimed to
determine not only the effects of a HFD, but also if such
effects could be counteracted by metformin treatment, the
animals receiving a HFD were divided into two groups
(after 10 weeks of dietary treatment) - where eight animals
received oral gavage administration of 300 mg/kg/day
metformin and the remaining eight animals received oral
administration of saline. Volumes administered ranged be-
tween 0.128 – 0.235 ml/day. After 14 consecutive days of
metformin/saline administration – 12 weeks after the initi-
ation of the study – animals were euthanized using carbon
dioxide. Throughout the study, weight and food consump-
tion for all animals/cages were recorded once a week.
Blood glucose and HbA1c
Blood samples for glucose measurements were obtained
from each mouse by needle puncture of the tail tip vein.
Both prandial and fasting glycemia were measured at three
time points (before initiation of metformin/saline treat-
ment [time 0], 1 week after initiation [time 1] and 2 weeks
after initiation before the end of the study [time 2]). Blood
glucose concentrations were determined by means of
Bayer’s Elite® Glucometer and compatible blood glucose
test strips. Fasting blood samples for HbA1c measure-
ments were obtained at time 0 and time 2 from the same
puncture of the tail tip vein. HbA1c was determined using
a DCA Vantage® Analyzer (Siemens Healthcare Diagnos-
tics, Tarrytown, NY) and compatible sample cassettes.
Serum insulin, FFA and GLP-1 determinations
Blood samples were collected from the saphena vein
(approx. 50 μl – max. 8 ml/kg/2 weeks) after 6 h fasting
at time 0, 1 and 2 (see above), and transferred to centri-
fuge tubes at room temperature. At time 2, immediately
after euthanization, a heart puncture was also performed
and a larger volume of prandial blood collected. The blood
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in a freezer at −70°C for later analysis of insulin, total GLP-
1 (7–36 and 9–36), active GLP-1 (7–36) and FFAs. Serum
insulin concentrations were determined using a mouse ul-
trasensitive enzyme-linked immunosorbent assay (ELISA)
(Mercodia, Uppsala, Sweden), according to the manufac-
turer’s instructions. Serum GLP-1 (7–36 and 9–36) and
serum GLP-1 (7–36) were determined using specific ELI-
SAs (Millipore, Billerica, MA) according to the manufac-
turer’s instructions. Serum FFAs were determined using
the NEFA-HR(2) assay kit (Wako Chemicals, Richmond,
VA) according to its instructions.
Oral glucose tolerance test (OGTT)
Food was removed 6 h prior to oral gavage administration
of 1.5 g/kg glucose (50% glucose solution) at the end of
the last week of treatment. At 15, 30 and 60 min following
administration, blood samples for glucose measurements
were obtained from each mouse by needle puncture of the
tail tip vein. Blood glucose concentrations were deter-
mined by means of Bayer’s Elite® Glucometer and com-
patible blood glucose test strips.
Immunohistochemistry and quantification of L-cells
After euthanization, intestinal tissue was collected from
the animals. The intestine was extracted and carefully
removed of all fat. A 4-cm section proximal/distal to the
appendix was removed and carefully cut open to have
the lumen exposed and facing upward. The intestinal tis-
sue section was then rolled up, starting with the most
proximal end and with the lumen facing the center of
the roll. The rolls were attached to plastic caps and im-
mediately submerged in a freeze bath of 99% ethanol
and dry ice. The rolls were stored in a freezer at −70°C
pending sectioning of the intestinal tissue using a cryo-
stat. The intestinal tissue was sectioned using a cryostat
in 12 μm thick sections from the top of the roll towards
the bottom, leaving each section to expose the lumen
and villi of the full length of the intestinal tissue section.
These sections were placed in consecutive order on six
glass slides starting with position 1 of all slides, followed
by position 2 of all slides, etc., leaving each and all slides
with 10 sections representing the full cross section of
the lumen. Sections were stored at −70°C.
Prior to IHC, sections were washed in PBS and fixed
using a 10 min incubation with acetone at −20°C. Sec-
tions were then washed 3 × 10 min in PBS-T and incu-
bated overnight at 4°C with a rabbit antibody specific for
GLP-1 (Phoenix Europe GmbH, Karlsruhe, Germany.
Cat# H-028-11) at 1:500 dilution in PBS-T containing
5% donkey serum. Tissue sections were washed in PBS-
T 3 × 10 min and incubated for 2 h at room temperature
in the dark with the secondary antibody (ALEXA Fluor 488
conjugated donkey anti-rabbit) (Invitrogen) at 1:200dilution in PBS-T. Sections were washed in PBS 3 × 10 min
and allowed to dry before a cover glass was mounted using
Polyvinyl Alcohol mounting medium with DABCO antifad-
ing (Fluka Biochemica, Ronkonkoma, NY). For the purpose
of quantifying cells after IHC, an advanced stereology plat-
form, which allows unbiased quantification of cell number/
volume and structural measurements within the intestinal
structure [15], was used. Suboptimal quality of some of the
pictures obtained from immunostaining of intestinal tissue
resulted from technical difficulties associated with intestinal
side effects of the combination of dietary treatment and
metformin, as well as the relatively limited life-span of cryo-
sections due to the formation of ice crystals Cross-sections
from the distal intestine were analyzed from each of three
animals from the different treatment groups.
Statistical analysis
Comparisons between groups, treatments and time were
made by a one-way ANOVA for repeated measures.
Newman-Keul’s post-hoc test was used. Comparisons be-
tween control and single treatment groups were done
using two-tailed Student’s t test. Correlations were evalu-
ated by determining the Pearson correlation coefficients.
P < 0.05 was deemed statistically significant. Power ana-
lysis was performed and taken into consideration for all
experiments performed.
Results
After 10 weeks, C57/Bl6 mice on a high fat diet display a
significant increase in body weight and a diabetic
phenotype characterized by hyperglycemia and fasting
hyperinsulinemia
After 10 weeks on a HFD, mice had significantly in-
creased in body weight (Figure 1A) while food intake
was slightly – but significantly – reduced (Figure 1B).
To determine if the HFD treatment had induced a diabetic
phenotype, we analyzed glycemia, HbA1c and fasting
serum insulin levels. We could determine a significant
increase in fasting blood glucose (Figure 1C), HbA1c
(Figure 1D) and fasting serum insulin levels (Figure 1E),
33%, 15% and 70% increase, respectively. In addition,
serum was analyzed for the active form of GLP-1 (7–36)
as well as total levels of GLP-1, including both the active
peptide GLP-1 (7–36) and the metabolite GLP-1 (9–36).
However, no difference in fasting active or total GLP-1
levels could be observed after 10 weeks on a HFD (con-
trol diet 22.1 ± 2.4 pM vs. HFD 23.0 ± 2.7 pM).
Metformin significantly improves glycemia, fasting serum
insulin and oral glucose tolerance
Gauge feeding caused some nausea, reduced food intake
and induced weight loss in all groups. The greatest reduc-
tion in food intake was observed in the groups receiving a
HFD, where food intake was at its lowest among those
Figure 1 After 10 weeks, C57/Bl6 mice on a high fat diet display a significant increase in body weight and a diabetic phenotype
characterized by hyperglycemia and fasting hyperinsulinemia. The average weight of the animals receiving a HFD is noticeably and
significantly increased already after 1 week and continues to increase over 10 weeks (A). The average daily food intake (B) is slightly, but significantly,
lower in the same group. Fasting blood glucose (C) and HbA1c (D), as well as fasting insulin (E) levels were significantly higher in mice receiving HFD;
33%, 15% and 70% increase, respectively (n = 16 for control diet group, n = 16 for HFD group). Bars represent mean ± SEM. ***, p < 0.001 compared
with control group. Statistical analysis was performed using Student’s t-test.
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conjunction with the data representing food intake, a
relatively large additive weight loss was observed in the
HFD +metformin group (Figure 2A-C). To determine
the effect of metformin treatment on hyperglycemia and
increased fasting serum insulin observed in mice on a
HFD, these parameters were analyzed at the end of a
two week treatment with metformin. An oral glucose
tolerance test (OGTT) was also performed. Our results
demonstrate that metformin significantly reduced HbA1c
(Figure 2D) and fasting serum insulin (Figure 2E)
levels, i.e. a 20% and 60% decrease, respectively, was in-
dicated. Considering the significant weight loss in HFD
groups, we wanted to determine if weight could be anindependent parameter regulating glycemia/serum insu-
lin. Our data show a positive correlation between weight
and HbA1c (correlation coefficient: 0.683; p < 0.01).
However, serum insulin levels cannot be correlated to
weight alone. We also determined glucose tolerance
using an OGTT. Glucose tolerance is significantly
compromised in mice receiving a HFD as indicated by
an elevated glucose peak (37% increase in plasma glu-
cose 15 min following oral glucose load) and signifi-
cantly higher glucose levels also 30 min after oral
administration (Figure 2F-G). Nevertheless, daily oral
administration of metformin for 14 days will significantly
attenuate the glucose peak and blood glucose levels
30 min following oral administration (Figure 2G).
Figure 2 Metformin significantly improves glycemia, fasting serum hyperinsulinemia and oral glucose tolerance. Starting from week 1 of
treatment, food intake was reduced in all groups but predominantly in the groups receiving HFD, where the metformin group displayed the largest
decrease (A). Due to the relatively short treatment period, and food intake being determined at only two time points (at the end of week 1 and week 2),
statistical significance could not be calculated. The weight of the animals reflects the reduced food intake (B, C), where the weight loss is greatest in
animals receiving metformin in combination with HFD. HbA1c (D) and fasting serum insulin (E) levels are significantly increased in the HFD group, and
significantly reduced (20% and 60% decrease, respectively) by a 14 day oral administration of 300 mg/day metformin. Glucose tolerance (F,G) is
significantly decreased in mice receiving a HFD (37% increase in plasma glucose 15 min following oral glucose load), and significantly improved
following a 14 day oral administration of 300 mg/day metformin; 6% reduction in plasma glucose (n = 8 for control diet group, n = 6 for HFD group,
n = 4 for HFD group receiving metformin). Bars represent mean ± SEM. * and ** denote p < 0.05 and p < 0.01, respectively, compared with control group.
#, p < 0.05 compared with HFD group. Statistical analysis was performed using one-way ANOVA.
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free fatty acids and reduces the number of GLP-1-positive
cells in the distal intestine while upregulating intestinal
expression of GLP-1R mRNA
Animals on a HFD had significantly more epididymal fat
and prandial serum FFAs; however, these parameters were
reduced in animals on a HFD also receiving metformin
(Figure 3A-C). To determine if obesity and hyperlipidemia
could induce a lipotoxic effect in these animals, as ob-
served in vitro, resulting in reduced GLP-1-positive cell
number and GLP-1 secretory capacity, we quantified
GLP-1-positive cells in extracted intestinal tissue, using
IHC and stereological methods. In line with a lipotoxicFigure 3 A high fat diet significantly increases epididymal fat, serum
the distal intestine. Epididymal fat (A-B) and fasting serum free fatty acid
increase, respectively) and reduced by a 14-day 300 mg/day metformin tre
group, n = 6 for HFD group, n = 4 for HFD group receiving metformin). The
in intestinal tissue sections from animals on HFD (D and G) as compared t
an effect indicated to be reversed by daily administration of metformin for
bar: 25 μm. No significant effect can be determined of a HFD or metformin
HFD - 46% increase, p = 0.095 and HFD +metformin – 72% increase, p = 0.2
in response to a HFD (53% increase), while normalized by metformin treatm
group receiving metformin). GLP-1R mRNA expression was normalized with
A.u.; Arbitrary units (I). Bars represent mean ± SEM. *, p < 0.05 compared wi
analysis was performed using one-way ANOVA.effect, we observed an indicated reduced number of
GLP-1-positive cells in intestinal tissue sections from
animals on a HFD (Figure 3D,G) as compared to ani-
mals receiving a control diet (Figure 3E,G). Specifically,
a 55% reduction of the number of GLP-1-positive cells
was indicated in the HFD group, with a p-value of 0.134.
This effect was indicated to be reversed by daily adminis-
tration of metformin for 14 consecutive days (f and g),
However, there was not a significant difference between
the two groups in terms of the intestinal expression of pro-
glucagon mRNA (average mRNA expression after control
diet 142 ± 26 vs. HFD 198 ± 73 [arbitrary units]). Further,
fasting serum GLP-1 (7–36) levels were determined butfree fatty acids and reduces the number of GLP-1-positive cells in
s (C) are significantly increased in animals receiving HFD (55% and 41%
atment (22% and 59% reduction, respectively). (n = 8 for control diet
re is a trend towards a reduced number of GLP-1-immunopositive cells
o animals receiving a control diet (E and G); 55% reduction, p = 0.134,
14 consecutive days (F and G), (n = 3 for each treatment group). Scale
treatment on prandial serum GLP-1 (7–36 and 9–36) levels (H);
3. Intestinal expression of GLP-1R mRNA was significantly upregulated
ent. (n = 8 for control diet group, n = 6 for HFD group, n = 4 for HFD
mRNA expression of GAPDH, which was used as an internal control.
th control group. #, p < 0.05 compared with HFD group. Statistical
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(data not shown). As GLP-1 secretion is increased after
nutrient intake, we also determined prandial GLP-1 (7–
36 and 9–36) levels. Results from these studies indicate
a trend toward increased prandial serum GLP-1 levels
in animals receiving a HFD; however, this difference did
not attain statistical significance. Further, treatment
with metformin, while reducing epididymal fat and FFA
levels, tends to enhance serum GLP-1 levels in animals
receiving a HFD (Figure 3G). Further, in line with re-
sults from previous in vitro studies [6], metformin treat-
ment reduced the intestinal expression of proglucagon
(average mRNA expression after HFD-saline 198 ± 73 vs.
HFD-metformin 49 ± 7 [arbitrary units]). Interestingly, in-
testinal expression of GLP-1R mRNA was significantly up-
regulated in response to a HFD, while normalized by
metformin treatment (Figure 3H).
Discussion
Animals on a HFD develop hyperglycemia in conjunc-
tion with hyperlipidemia, indicating the manifestation of
insulin resistance. The improved glycemia, fasting serum
insulin and oral glucose tolerance observed in response
to metformin treatment was expected and in line with
the known anti-diabetic properties of metformin [16,17].
The oral gavage administration did cause nausea and re-
duced food intake during the 14 days of treatment,
where those mice receiving a HFD displayed significantly
reduced appetite. Further, metformin treatment initially
induced diarrhea. Starting with a lower dosage and in-
creasing up to desired dosage over 3–4 days may have
avoided this side-effect of metformin treatment. To de-
tect if the weight loss during treatment was a confound-
ing factor for the beneficial effects of metformin, we
evaluated weight as an independent parameter for the
improved metabolic state. The fact that weight alone dis-
played a significant positive correlation with HbA1c, but
not fasting serum insulin, indicates that – although the
weight loss most likely contributed to the beneficial ef-
fects – metformin treatment was indeed effective. In
contrast to numerous reports of enhanced GLP-1 secre-
tion in response to dietary fat [7,8], no significant in-
crease in fasting or prandial GLP-1 (7–36 and/or 9–36)
could be detected in our animals fed a HFD. This dis-
crepancy may stem from differences in the fatty acid
stimuli; lipid load/HFD, as well as the duration of the
HFD. In fact, many of the before mentioned studies in-
vestigating effects of fatty acids on GLP-1 secretion have
focused on acute effects, and it can be hypothesized that
toxic effects of chronic hyperlipidemia and reduced L-
cell mass at some stage outweigh the stimulatory effect
of the enteral fatty acids on GLP-1 secretion, i.e. exceed-
ing the ability of the remaining L-cells to compensate.
Extending the duration of the HFD may thus eventuallyresult in a defective postprandial GLP-1 response, while
reducing the duration of the HFD may result in observa-
tions of increased plasma GLP-1 in this group, as was
indeed recently demonstrated [18]. This hypothesis is
supported by the trend toward reduced numbers of GLP-
1-positive cells detected in the intestinal tissue from HFD-
fed mice as compared to intestinal tissue from mice
receiving a control diet, and in line with reports of a nega-
tive correlation between GLP-1 plasma levels and BMI
[12]. Further, metformin was indicated to counteract such
effects of a HFD on the number of GLP-1-positive cells.
Detrimental effects only after persistent and long term ex-
posure to hyperlipidemia could theoretically be explained
by an accumulation of FFAs that eventually exceeds the
capacity of the L-cell for triglyceride storage and the sub-
sequent increase in β-oxidation and ROS production
[10,13]. However, measurement of plasma GLP-1 in the
different treatment groups following a glucose load would
have added to the understanding of potential effects of a
high fat diet and metformin treatment on the incretin re-
sponse, and should be undertaken in future studies.
The present study shows reduced intestinal progluca-
gon expression in mice on a HFD following metformin
treatment, which aligns well with previously published
in vitro data, indicating metformin stimulatory action to
be at the level of secretion. However, if metformin treat-
ment increases the number of viable GLP-1-positive
cells after a HFD, an increased intestinal proglucagon
expression would be expected despite possible counter-
acting effects of metformin on proglucagon expression
at the level of individual L-cells. The interpretation of
the available data from this study is made even more dif-
ficult due to the adverse gastrointestinal side-effects in-
duced by the metformin treatment, and the relatively
short duration of metformin treatment. Therefore, fur-
ther studies are necessary to confirm whether metformin
lipoprotection can be observed in vivo, or is purely an
in vitro phenomenon. The upregulation of GLP-1R
mRNA in response to a HFD – and normalization
thereof by metformin treatment – provokes further as-
sessment of the intestinal expression of the GLP-1R
under these conditions. Further, the mechanisms behind
such effects remain to be investigated. It is, in light of a
defective incretin response in diabetic patients improved
by metformin treatment, tempting to hypothesize that
compensatory mechanisms underlie increased receptor
expression in response to reduced levels of the ligand and/
or defective GLP-1R signaling in HFD-induced T2D.
In conclusion, our findings provide evidence for rapid
development of insulin resistance and diabetes in mice
receiving a HFD, with a significant improvement in re-
sponse to metformin, which also was indicated to im-
prove the prandial incretin response of HFD-fed mice.
Further, our data demonstrate a clear trend toward
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However, considering no significant effect on fasting or
prandial levels of GLP-1 in response to HFD, any reduc-
tion in the number of GLP-1-positive cells seemingly
does not contribute to the development of oral glucose
intolerance, hyperinsulinemia and hyperglycemia in this
study. It may rather contribute to the progression of the
diabetic state as it may lead to decreased prandial GLP-1
secretion when the reduction of GLP-1-positive cell
number in response to hyperlipidemia overtakes fatty
acid-induced potentiation of GLP-1 secretion.
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